These data corroborate previous reports demonstrating that glutamine deprivation and GLS gene silencing reduces glioma cell proliferation, with IDH-mutant glioma cells exhibiting particular sensitivity to GLS inhibitors/glutamine antagonists or GLS gene silencing [60, 61]. Here, IDH1 is linked to central nervous system cancer.